Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10435972" target="_blank" >RIV/00064203:_____/22:10435972 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=h5uYCsqfRM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=h5uYCsqfRM</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.14634" target="_blank" >10.1111/dom.14634</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial

Popis výsledku v původním jazyce

AIMS: Diabetes mellitus is an independent risk factor for atrial fibrillation or atrial flutter (atrial arrythmia, AA). Additionally, some diabetes medications may influence AA incidence. The aim of this post hoc analysis was to assess the occurrence of AA during the study period in patients with type 2 diabetes treated with once weekly subcutaneous dulaglutide vs placebo in the REWIND study. MATERIALS AND METHODS: Patients without electrocardiographic (ECG) confirmed AA at baseline and randomised in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared to placebo reduced the composite outcome of AA or death, AA or CV death, AA or stroke and AA or heart failure. RESULTS: Among 9543 participants (mean age 66 +- 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, vs. 255 of the 4774 allocated to placebo (5.3%) at a rate of 10.5 per 1000 person-years (p=0.59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. CONCLUSION: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes. This article is protected by copyright. All rights reserved.

Název v anglickém jazyce

Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial

Popis výsledku anglicky

AIMS: Diabetes mellitus is an independent risk factor for atrial fibrillation or atrial flutter (atrial arrythmia, AA). Additionally, some diabetes medications may influence AA incidence. The aim of this post hoc analysis was to assess the occurrence of AA during the study period in patients with type 2 diabetes treated with once weekly subcutaneous dulaglutide vs placebo in the REWIND study. MATERIALS AND METHODS: Patients without electrocardiographic (ECG) confirmed AA at baseline and randomised in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared to placebo reduced the composite outcome of AA or death, AA or CV death, AA or stroke and AA or heart failure. RESULTS: Among 9543 participants (mean age 66 +- 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, vs. 255 of the 4774 allocated to placebo (5.3%) at a rate of 10.5 per 1000 person-years (p=0.59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. CONCLUSION: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes. This article is protected by copyright. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes, Obesity &amp; Metabolism

ISSN

1462-8902

e-ISSN

1463-1326

Svazek periodika

24

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

704-712

Kód UT WoS článku

000746220400001

EID výsledku v databázi Scopus

2-s2.0-85123496387